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We describe the effects of the 7-valent (PCV7) and 13-va-
lent (PCV13) pneumococcal conjugate vaccines on pneu-
mococcal meningitis in England and Wales during July 1, 
2000–June 30, 2016. Overall, 84,473 laboratory-confirmed 
invasive pneumococcal disease cases, including 4,160 
(4.9%) cases with meningitis, occurred. PCV7 implementa-
tion in 2006 did not lower overall pneumococcal meningi-
tis incidence because of replacement with non–PCV7-type 
meningitis incidence. Replacement with PCV13 in 2010, 
however, led to a 48% reduction in pneumococcal menin-
gitis incidence by 2015–16. The overall case-fatality rate 
was 17.5%: 10.7% among patients <5 years of age, 17.3% 
among patients 5–64 years of age, and 31.9% among pa-
tients >65 years of age. Serotype 8 was associated with 
increased odds of death (adjusted odds ratio 2.9, 95% CI 
1.8–4.7). In England and Wales, an effect on pneumococcal 
meningitis was observed only after PCV13 implementation. 
Further studies are needed to assess pneumococcal men-
ingitis caused by the replacing serotypes.
Streptococcus pneumoniae is a major cause of bacterial meningitis across all age groups in the United Kingdom 
and worldwide (1,2); the case-fatality rate (CFR) ranges 
from 10% to 40% (2–4). Survivors of pneumococcal men-
ingitis are more likely than survivors of other types of 
bacterial meningitis to have neurologic and other serious 
long-term sequelae (5,6); a meta-analysis indicated that 
32% of pneumococcal meningitis patients experienced se-
quelae (7). The pathophysiologic mechanisms leading to 
neurologic damage in patients with bacterial meningitis are 
complex and multifaceted, involving the secretion of po-
tent bacterial toxins and excessive host immune responses 
against the invading pneumococci in the cerebrospinal 
fluid (8,9).
Before the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7), ≈500 confirmed pneumococcal 
meningitis cases occurred annually in England and Wales 
(2). The serotypes covered by PCV7 were responsible for 
57% of all pneumococcal meningitis cases and 72% of cas-
es in children <2 years of age; the CFR increased with age, 
from 5% in children to 30% in older adults (10).
In September 2006, the United Kingdom introduced 
PCV7 into the childhood immunization program; chil-
dren were scheduled to receive the vaccine at 2, 4, and 12 
months of age, and a 12-month catch-up program was es-
tablished for children <2 years of age (11). The program 
was associated with a rapid decline in invasive pneumococ-
cal disease (IPD) caused by PCV7 serotypes, and although 
some increase in IPD caused by non-PCV7 serotypes was 
observed, IPD decreased overall by 36% compared with 
pre-PCV7 levels through direct and indirect protection 
(12). During the first 4 years of the program, a 34% reduc-
tion in pneumococcal meningitis incidence was observed 
in children <5 years of age (13). However, this reduction 
was almost entirely offset by an increase in meningitis 
cases caused by non-PCV7 serotypes in older children and 
adults. After PCV7 introduction, pneumococcal meningitis 
was mainly caused by serotypes 1, 3, 7F, 19A, 22F, and 
33F (14).
In April 2010, PCV7 was replaced with the 13-va-
lent vaccine (PCV13), which led to a 32% reduction in 
overall IPD incidence compared with pre-PCV7 levels 
and a 56% reduction compared with pre-PCV13 levels 
(14). The effect of PCV13 on pneumococcal meningitis 
has not been assessed in the United Kingdom. Reports of 
the effects of PCV7 and PCV13 on pneumococcal men-
ingitis in other countries with established pneumococcal 
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Pneumococcal Meningitis in England and Wales
immunization programs have been variable; in some coun-
tries, significant reductions were reported after PCV7 in-
troduction, and in other countries, no change or a decline 
was reported only after PCV13 introduction (15–20). 
Here, we describe the epidemiology of pneumococcal 
meningitis in England and Wales over a 16-year period 
encompassing the introduction of PCV7 and PCV13 into 
the national immunization program.
Methods
Surveillance
Public Health England (PHE; London, England, UK) has 
legal permission under Regulation 3 of the Health Service 
(Control of Patient Information) Regulations 2002 (http://
www.legislation.gov.uk/uksi/2002/1438/regulation/3/
made) to conduct national surveillance of communicable 
diseases. This regulation also provides PHE permission to 
access information required to monitor the safety and ef-
fectiveness of vaccines.
PHE conducts surveillance for IPD and provides a 
national reference service for serotyping pneumococcal 
isolates in England and Wales (12). Staff of the National 
Health Service laboratories electronically report invasive 
bacterial infections to PHE by using the Second Generation 
Surveillance System, which replaced LabBase2 in 2014, 
and routinely submit all invasive pneumococcal isolates to 
the PHE national reference laboratory for confirmation and 
serotyping (12). PHE staff actively follow up on reported 
cases when they do not receive an accompanying isolate. 
Case ascertainment has remained consistently high, espe-
cially for meningitis cases; >90% of invasive pneumococ-
cal isolates are submitted to PHE for serotyping (12). Start-
ing in September 2006, IPD surveillance was enhanced by 
the collection of 1-page surveillance questionnaires com-
pleted by the patient’s general practitioner; questionnaires 
asked for information on patients’ vaccination histories, 
underlying medical conditions, and outcomes.
Data Analysis
We exported anonymized (mainly descriptive) data to Stata 
v.11.0 (https://www.stata.com) for analysis. We included 
laboratory-confirmed cases of pneumococcal meningitis 
diagnosed during July 1, 2000–June 30, 2016 (16 epide-
miologic years). We defined meningitis as identification of 
S. pneumoniae in cerebrospinal fluid or blood cultures of 
patients with a clinical diagnosis of meningitis, as desig-
nated on their electronic report or sample submission form 
sent to PHE. Excluding clinically diagnosed cases in which 
S. pneumoniae was not confirmed in the cerebrospinal fluid 
(25%–35% of all pneumococcal meningitis cases annually) 
reduced the total number of meningitis cases available for 
analysis without affecting the observed trends over time. 
We identified fatal cases and dates of death through the pa-
tient demographic service and calculated the 30-day CFR.
We classified cases into 4 groups by serotype: PCV7 
(serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), additional PCV13 
(serotypes 1, 3, 5, 6A, 7F, 19A), non-PCV13, and unknown 
(typically resulting from lack of referral or unsuccessful re-
covery from culture after sample transport). We analyzed 
cases as a whole and by patient age group (<5, 5–64, >65 
years). We filled in missing age and serotype by assuming 
that age and serotype distribution were the same on reports 
with missing information as on reports for which these pa-
rameters were known. We obtained age-specific popula-
tion denominators from the Office for National Statistics 
(www.statistics.gov.uk) and compared the adjusted annual 
incidence rates for pneumococcal meningitis in epidemio-
logic year 2015–16 with rates for the pre-PCV7 (July 1, 
2000–June 30, 2006) and pre-PCV13 (July 1, 2008–June 
30, 2010) periods by age and serotype group, assuming a 
Poisson distribution.
For cases diagnosed during the PCV13 period (July 
1, 2011–June 30, 2016), we used multivariable logistic re-
gression to calculate the odds of meningitis (vs. nonmenin-
gitis) for individual serotypes (vs. all other serotypes) after 
adjusting for age group and surveillance year. We also used 
multivariable logistic regression to calculate the odds of 
death by clinical presentation (meningitis vs. nonmeningi-
tis) after adjusting for age group and surveillance year. For 
meningitis cases, we used multivariable logistic regression 
to assess the odds of death by age group, serotype group, 
individual serotype (vs. all other serotypes), and surveil-
lance year after adjusting for age group and surveillance 
year. Because of multiple comparisons, we considered 
p<0.01 to be significant. We estimated the cases prevented 
according to age group by determining the difference be-
tween the expected (average corrected number of cases in 
absence of vaccination) and observed numbers of cases af-
ter the introduction of each vaccine.
Results
During the 16-year surveillance period, 84,473 laborato-
ry-confirmed IPD cases occurred across all age groups; 
4,160 (4.9%) cases were meningitis and 80,313 (95.1%) 
were nonmeningitis. Of the 4,108 meningitis cases with 
age reported, 1,611 (39.2%) were in children <5 years of 
age, 1,729 (42.1%) in persons 5–64 years of age, and 768 
(18.7%) in adults >65 years of age. Of the 79,620 nonmen-
ingitis cases with age reported, 8,324 (10.5%) were in chil-
dren <5 years of age, 32,297 (40.6%) in persons 5–64 years 
of age, and 38,999 (48.9%) in adults >65 years of age.
Before PCV7 introduction, the mean annual incidence 
of pneumococcal meningitis was 0.55 cases/100,000 per-
son-years (Table 1). The childhood PCV7 program had 
no effect on the overall annual incidence of pneumococcal 
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Table 1. Cases, incidence, and age-adjusted IRRs for pneumococcal meningitis and nonmeningitis cases by age group, serotype 
group, and period, England and Wales, July 1, 2000–June 30, 2016* 
Case type, age group, 
and serotype group 
July 1, 2015– 
June 30, 2016 
 Pre-PCV13 period, July 1, 2008– 
June 30, 2010 
 Pre-PCV7 period, July 1, 2000– 
June 30, 2006 
No. 
corrected 
(raw) 
cases† 
Incidence, 
cases/ 
100,000 
person-
years 
No. 
corrected 
(raw) 
cases† 
Incidence, 
cases/ 
100,000 
person-
years 
IRR (95% CI) 
vs. 2015–16  
No. 
corrected 
(raw) 
cases† 
Incidence, 
cases/ 
100,000 
person-
years 
IRR (95% CI) 
vs. 2015–16  
Meningitis 
 <5 y 
  All serotypes 41 (44) 1.22  105 (104) 3.10 0.39 (0.25–0.63)  138 (122) 4.08 0.30 (0.19–0.46) 
  PCV7 1 (1) 0.03  10 (10) 0.29 0.10 (0.01–1.84)  102 (76) 3.02 0.01 (0–0.16) 
  Additional PCV13 3 (3) 0.09  53 (51) 1.56 0.06 (0.01–0.29)  18 (14) 0.54 0.16 (0.03–0.85) 
  Non-PCV13 37 (38) 1.10  42 (41) 1.25 0.89 (0.51–1.56)  18 (13) 0.52 2.12 (1.22–3.75) 
 5–64 y 
  All serotypes 96 (98) 0.22  155 (155) 0.36 0.62 (0.44–0.86)  117 (110) 0.27 0.82 (0.60–1.11) 
  PCV7 2 (2) 0.00  28 (27) 0.07 0.07 (0.01–0.56)  54 (39) 0.13 0.04 (0.01–0.29) 
  Additional PCV13 14 (13) 0.03  51 (47) 0.12 0.27 (0.11–0.62)  22 (16) 0.05 0.62 (0.26–1.39) 
  Non-PCV13 80 (77) 0.19  76 (71) 0.18 1.06 (0.71–1.58)  41 (29) 0.10 1.95 (1.31–2.86) 
 >65 y 
  All serotypes 24 (28) 0.27  52 (52) 0.59 0.46 (0.25–0.85)  53 (49) 0.60 0.45 (0.26–0.80) 
  PCV7 0 (0) 0  8 (8) 0.09 0 (0–0.52)  23 (17) 0.26 0 (0–0.17) 
  Additional PCV13 2 (2) 0.02  11 (10) 0.12 0.19 (0.02–1.57)  10 (7) 0.11 0.20 (0.02–1.55) 
  Non-PCV13 22 (22) 0.25  33 (32) 0.37 0.67 (0.33–1.34)  20 (15) 0.22 1.11 (0.56–2.18) 
 All ages 
  All serotypes 162 (170) 0.29  311 (310) 0.56 0.51 (0.40–0.66)  301 (288) 0.55 0.52 (0.41–0.65) 
  PCV7 3 (3) 0.01  46 (44) 0.08 0.07 (0.01–0.35)  176 (133) 0.32 0.02 (0–0.09) 
  Additional PCV13 18 (18) 0.03  114 (108) 0.21 0.16 (0.08–0.32)  49 (38) 0.09 0.36 (0.18–0.72) 
  Non-PCV13 141 (137) 0.25  151 (143) 0.27 0.92 (0.69–1.25)  77 (58) 0.14 1.77 (1.33–2.36) 
Nonmeningitis 
 <5 y 
  All serotypes 241 (257) 7.12  345 (341) 10.19 0.70 (0.57–0.86)  666 (592) 19.67 0.36 (0.30–0.44) 
  PCV7 5 (5) 0.15  25 (23) 0.74 0.21 (0.05–0.79)  479 (310) 14.17 0.01 (0–0.04) 
  Additional PCV13 30 (29) 0.89  217 (199) 6.40 0.14 (0.08–0.24)  112 (73) 3.30 0.27 (0.15–0.46) 
  Non-PCV13 206 (198) 6.08  103 (95) 3.05 2.00 (1.50–2.66)  75 (49) 2.20 2.76 (2.11–3.57) 
 5–64 y 
  All serotypes 2,333 
(2,387) 
5.44  2,385 
(2,377) 
5.56 0.98 (0.91–1.05)  2,141 
(2,028) 
4.99 1.09 (1.01–1.16) 
  PCV7 57 (55) 0.13  313 (274) 0.73 0.18 (0.12–0.28)  865 (465) 2.02 0.07 (0.04–0.10) 
  Additional PCV13 375 (359) 0.87  1,163 
(1,022) 
2.71 0.32 (0.27–0.38)  651 (366) 1.52 0.57 (0.46–0.64) 
  Non-PCV13 1,901 
(1,820) 
4.43  909 (799) 2.12 2.09 (1.90–2.30)  625 (355) 1.46 3.04 (2.74–3.30) 
 >65 y 
  All serotypes 2,442 
(2,818) 
27.29  2,417 
(2,391) 
27.01 1.01 (0.94–1.08)  2,820 
(2,601) 
31.51 0.87 (0.82–0.92) 
  PCV7 49 (53) 0.55  402 (351) 4.49 0.12 (0.08–0.18)  1,466 
(775) 
16.39 0.03 (0.02–0.05) 
  Additional PCV13 422 (455) 4.71  913 (803) 10.20 0.46 (0.40–0.53)  574 (318) 6.42 0.73 (0.61–0.82) 
  Non-PCV13 1,971 
(2,127) 
22.03  1,103 
(970) 
12.32 1.79 (1.63–1.95)  779 (411) 8.70 2.53 (2.34–2.77) 
 All ages 
  All serotypes 5,217 
(5,467) 
9.44  5,135 
(5,116) 
9.30 0.98 (0.93–1.02)  5,563 
(5,321) 
10.07 0.89 (0.85–0.93) 
  PCV7 115 (113) 0.21  735 (648) 1.33 0.15 (0.11–0.20)  2,813 
(1,571) 
5.09 0.04 (0.03–0.05) 
  Additional PCV13 862 (844) 1.56  2,290 
(2,026) 
4.15 0.36 (0.33–0.41)  1,311 
(767) 
2.37 0.60 (0.53–0.66) 
  Non-PCV13 4,239 
(4,148) 
7.67  2,109 
(1,866) 
3.82 1.92 (1.80–2.05)  1,439 
(804) 
2.61 2.75 (2.59–2.92) 
*PCV7 refers to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, and additional PCV13 refers to serotypes 1, 3, 5, 6A, 7F, and 19A. Non-PCV13 refers to all 
other serotypes. IRR, incident rate ratio; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. 
†Raw numbers of cases for each year were corrected for missing serotype and age with the assumption that cases with missing data for age, serotype, or 
both had the same age and serotype distributions as those cases in which this information was known—the number of extra cases were then added to the 
raw numbers in each category; cases were also corrected for annual changes in population denominators in each age group (13). 
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meningitis (pre-PCV13 period 0.56 cases/100,000 person-
years) because the decline in PCV7-type meningitis was 
offset by substantial increases in cases caused by other sero-
types (Table 1; Figure 1). PCV7 replacement with PCV13 
in April 2010, however, led to a 48% (95% CI 38%–62%) 
reduction in pneumococcal meningitis incidence by 2015–
16. During the PCV13 period, meningitis cases caused by 
PCV7 and PCV13 serotypes continued to decline, and cas-
es associated with non-PCV13 serotypes remained static. 
These findings are in contrast with those regarding non-
meningitis IPD cases, in which reductions were observed 
across all age groups but were offset by increases in cases 
caused by nonvaccine serotypes after the introduction of 
PCV7 and PCV13 (Table 1). The serotypes responsible for 
meningitis varied among the pre-PCV7, pre-PCV13, and 
PCV13 periods (Figure 2).
Although meningitis cases were ≈20 times less com-
mon than nonmeningitis cases during the 16-year period, 
the contribution of individual serotypes to these 2 clinical 
presentations was similar (Figure 3). During the PCV13 
period, after adjusting for age and year of diagnosis, odds 
of causing meningitis were higher for only serotypes 10A, 
22F, 23B, and 35B and lower for serotypes 1, 8, and 19A 
(Table 2).
Cases in Patients <5 Years of Age
Pneumococcal meningitis cases in children increased from 
birth and peaked at 5 months of age, before gradually declin-
ing (Figure 4). For patients <5 years of age, PCV7 serotypes 
contributed to 73.9% (102/138), additional PCV13 to 13.0% 
(18/138), and non-PCV13 to 13.0% (18/138) of pneumo-
coccal meningitis cases during the pre-PCV7 period (Table 
1). After PCV7 introduction, pneumococcal meningitis in-
cidence fell from 4.08 cases/100,000 person-years to 3.10 
cases/100,000 person-years in the pre-PCV13 period (Table 
1). The rapid decline in PCV7-type meningitis (3.02 cas-
es/100,000 person-years [pre-PCV7] to 0.29 cases/100,000 
person-years [pre-PCV13]) was offset by an ≈3-fold in-
crease in PCV13-type disease incidence (0.54 cases/100,000 
person-years to 1.56 cases/100,000 person-years), nearly all 
caused by serotypes 7F (4 cases/year to 26 cases/year), 19A 
(3 cases/year to 15 cases/year), and 1 (2 cases/year to7 cases/
year). In this age group, the incidence of non-PCV13 men-
ingitis also increased from 0.52 cases/100,000 person-years 
to 1.25 cases/100,000 person-years in the pre-PCV13 period.
After PCV13 introduction, meningitis incidence de-
clined to 1.22 cases/100,000 person-years by 2015–16, 
a reduction of 70% (95% CI 54%–81%) from the pre-
PCV7 period (Table 1; Figure 1). This decline was caused 
by the continuing reduction in PCV7-type disease and a 
large reduction in the additional PCV13 serotypes (1.56 
cases/100,000 person-years [pre-PCV13] to 0.09 cases/ 
100,000 person-years [2015–16]) while meningitis incidence 
caused by non-PCV13 serotypes remained static. Nearly all 
cases in 2015–16 were caused by non-PCV13 serotypes, and 
only 3 cases were caused by a PCV13 serotype (Table 1, 
Figure 5).
Cases in Patients 5–64 Years of Age
Among patients 5–64 years of age, PCV7 serotypes were 
responsible for 46.2% (54/117), additional PCV13 for 
18.8% (22/117), and non-PCV13 for 35.0% (41/117) of 
pneumococcal meningitis cases during the pre-PCV7 pe-
riod. In this age group, meningitis incidence increased after 
PCV7 introduction, peaking in 2008–09 before declining 
after PCV13 introduction (Figure 1). After PCV7 intro-
duction, PCV7-type meningitis declined, and additional 
PCV13-type meningitis increased but then declined after 
PCV13 introduction. Meningitis caused by non-PCV13 
serotypes increased after PCV7 introduction and then sta-
bilized during the PCV13 period. During 2015–16, the ad-
ditional PCV13, especially serotype 3 (n = 5), caused some 
meningitis cases, but the non-PCV13 serotypes 12F (n = 
10) and 8 (n = 9) were the predominant causes of meningi-
tis; other serotypes caused only 1–2 cases.
Cases in Patients >65 Years of Age
Before PCV7 introduction, the serotype distribution among 
patients >65 years of age was similar to that of patients 
5–64 years of age, albeit with half the number of cases 
(Table 1). Meningitis incidence did not change after PCV7 
introduction (0.60 cases/100,000 person-years [pre-PCV7] 
to 0.59 cases/100,000 person-years [pre-PCV13]) but 
declined substantially after PCV13 introduction to 0.27 
cases/100,000 person-years by 2015–16, when serotypes 
8 (25.0%, 6/24) and 23B (16.7%,4/24) predominated. In 
2015–16, only 2 cases were caused by PCV13 serotypes 
(3 and 19A).
Case-Fatality Rate
The overall CFR for pneumococcal meningitis was 
17.5% (631/3,612; 95% CI 16.2%–18.7%) and pneumo-
coccal nonmeningitis 19.9% (14,783/74,179; 95% CI 
19.6%–20.2%). The CFR for pneumococcal meningi-
tis was 10.7% (150/1,408; 95% CI 9.1%–12.4%) among 
patients <5 years of age, 17.3% (262/1,517; 95% CI 
15.4%–19.3%) among patients 5–64 years of age, and 
31.9% (219/686; 95% CI 31.8%–39.5%) among patients 
>65 years of age. The CFR for pneumococcal nonmen-
ingitis was 3.5% (254/7,163) among patients <5 years of 
age, 10.8% (3,235/30,090) among patients 5–64 years of 
age, and 30.6% (11,292/36,907) among patients >65 years 
of age. The CFRs for patients with meningitis by serotype 
group were 14.2% (130/916) for PCV7 serotypes, 18.0% 
(143/793) for additional PCV13 serotypes, and 18.9% 
(290/1,534) for non-PCV13 serotypes.
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Figure 1. Corrected trends in incidence of pneumococcal meningitis and nonmeningitis cases by Streptococcus pneumoniae serotype, 
age group, and epidemiologic year, England and Wales, July 1, 2000–June 30, 2016. A–H) Meningitis (A, C, E, G) and nonmeningitis 
(B, D, F, H) cases in patients <5 years of age (A, B); patients 5–64 years of age (C, D); patients >65 years of age (E, F); and patients of 
all ages (G, H). The raw numbers of cases for each year were corrected for missing serotype and age with the assumption that cases 
with missing data for age, serotype, or both had the same age and serotype distribution as those cases for which this information was 
known; cases were also corrected for annual changes in population denominators in each age group (13).The vertical lines denote the 
introduction of PCV7 and PCV13 into the national childhood immunization program. PCV7 refers to serotypes 4, 6B, 9V, 14, 18C, 19F, 
and 23F, and additional PCV13 refers to serotypes 1, 3, 5, 6A, 7F, and 19A. Non-PCV13 refers to all other serotypes. PCV7, 7-valent 
pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
Pneumococcal Meningitis in England and Wales
In a logistic regression model, meningitis was associated 
with death (adjusted odds ratio [aOR] 1.6, 95% CI 1.4–1.7), 
independent of age group, serotype group, or period. Among 
meningitis cases, only increasing age (5–64 years aOR 1.7 
[95% CI 1.3–2.1] and >65 years aOR 3.9 [95% CI 3.1–5.0] 
vs. children <5 years of age; p<0.0001 for both) was inde-
pendently associated with death but not serotype group or 
surveillance year. In a logistic regression model comparing 
the CFR of serotypes associated with meningitis during the 
PCV13 period, only serotype 8 (CFR 33.7% [33/98] vs. CFR 
other serotypes 15.7% [123/783]) was associated with an in-
creased odds of death (aOR 2.9, 95% CI 1.8–4.7; p<0.0001).
Meningitis Cases Prevented
We estimated that 702 cases of meningitis were prevented 
during the 10 years since PCV7 introduction (2006–2016), 
mainly occurring after PCV13 introduction and nearly all 
in children <5 years of age. In total, 1,471 fewer cases 
were caused by PCV7 serotypes, and 173 more cases were 
caused by additional PCV13 serotypes (207 additional 
cases before PCV13 introduction and 34 fewer cases after 
PCV13 introduction).
Discussion
In England and Wales, pneumococcal meningitis ac-
counts for 5% of all IPD cases. Although large declines 
in IPD incidence were observed after PCV7 and PCV13 
introduction, we observed a differential impact on pneu-
mococcal meningitis and nonmeningitis. The annual 
incidence of pneumococcal meningitis remained un-
changed after PCV7 introduction but declined by 48% 
after PCV13 replaced PCV7. The greatest decline in 
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Figure 2. Mean annual number of pneumococcal meningitis cases among patients of all ages by Streptococcus pneumoniae serotype 
and period, England and Wales, July 1, 2000–June 30, 2016. The pre-PCV7 period refers to July 1, 2000–June 30, 2006, pre-PCV13 
period July 1, 2008–June 30, 2010, and PCV13 period July 1, 2011–June 30, 2016. PCV7, 7-valent pneumococcal conjugate vaccine; 
PCV13, 13-valent pneumococcal conjugate vaccine. For cases diagnosed during the PCV13 period (July 1, 2011–June 30, 2016), we 
used multivariable logistic regression to calculate the odds of meningitis vs. nonmeningitis. O, other serotypes.
Figure 3. Contribution of individual Streptococcus pneumoniae serotypes to pneumococcal meningitis and nonmeningitis cases for all age 
groups after PCV13 introduction, England and Wales, July 1, 2011–June 30, 2016. We included the non-PCV13 serotypes that involved 
>10 cases. PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine. O, other serotypes.
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pneumococcal meningitis incidence (70%) was observed 
among children <5 years of age. By 2015–16, PCV13-
serotype meningitis was rare, and nearly all cases were 
caused by non-PCV13 serotypes. The CFR, however, 
remained high (17.5%) and increased with age, but we 
found evidence of a lower CFR after both PCV7 and 
PCV13 implementation.
The reduction in PCV7-type pneumococcal men-
ingitis after PCV7 was introduced in 2006 was rapidly 
offset by an increase in cases caused by non-PCV7 sero-
types, especially 7F and 19A (later included in PCV13) 
and especially among adults (21). The replacement of 
PCV7 by PCV13 in 2010, however, led to large declines 
in pneumococcal meningitis cases, mainly because of an 
84% reduction in cases caused by the additional serotypes 
included in PCV13 without an increase in cases caused 
by non-PCV13 serotypes. Similar trends have been re-
ported in Israel, where meningitis incidence declined only 
after PCV13 introduction (22). In France, PCV7 imple-
mentation led to a rebound in incidence of pneumococcal 
meningitis, with a 2.2-fold increase among children, in-
cluding a 6.5-fold increase among those <2 years of age 
(23), followed by a 44% decline after PCV13 introduction 
(16,24). In contrast, many countries with established PCV 
programs reported declines in pneumococcal meningitis 
after implementation of each vaccine (18,25–31). In the 
United States, PCV7 implementation was associated with 
declines in PCV7-type pneumococcal meningitis across 
all age groups, but the overall incidence of pneumococ-
cal meningitis in adults did not change because disease 
with non-PCV7 serotypes increased (32). Possible expla-
nations for the variable observations include differences 
in immunization doses and schedules, implementation of 
catch-up programs along with vaccine introduction, vac-
cine uptake rates, rapidity of increases in disease attribut-
able to other serotypes after the introduction of each vac-
cine, and differences in the replacing serotypes’ abilities 
to cause IPD and meningitis.
We observed shifts in serotypes causing meningitis 
over time. Before PCV7 implementation, serotype 14 
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Table 2. Association between Streptococcus pneumoniae serotype and meningitis (vs. nonmeningitis) by serotype ranking, England 
and Wales, July 1, 2011–June 30, 1016* 
Serotype rank Serotype Total cases 
Nonmeningitis cases, 
n = 20,800, no. (%) 
Meningitis cases, 
n = 920, no. (%) aOR (95% CI) p value† 
1‡ 8 3,285 3,184 (15.3) 101 (11.0) 0.69 (0.56–0.86) <0.001 
2 12F 1,809 1,729 (8.3) 80 (8.7) 0.99 (0.78–1.27) 0.961 
3§ 22F 1,725 1,640 (7.9) 85 (9.2) 1.39 (1.1–1.76) 0.006 
4 3 1,598 1,542 (7.4) 56 (6.1) 0.99 (0.74–1.31) 0.924 
5 7F 1,542 1,482 (7.1) 60 (6.5) 0.73 (0.56–0.96) 0.026 
6‡ 19A 1,485 1,446 (7.0) 39 (4.2) 0.62 (0.45–0.86) 0.005 
7 15A 1,024 986 (4.7) 38 (4.1) 1.09 (0.78–1.54) 0.603 
8 9N 954 928 (4.5) 26 (2.8) 0.77 (0.51–1.15) 0.2 
9 33F 827 774 (3.7) 53 (5.8) 1.34 (0.99–1.81) 0.057 
10‡ 1 602 588 (2.8) 14 (1.5) 0.33 (0.19–0.56) <0.001 
11§ 10A 566 511 (2.5) 55 (6.0) 2.06 (1.52–2.79) <0.001 
12 23A 548 523 (2.5) 25 (2.7) 1.51 (1–2.29) 0.052 
13 24F 548 528 (2.5) 20 (2.2) 0.73 (0.46–1.16) 0.187 
14 6C 514 497 (2.4) 17 (1.8) 0.95 (0.58–1.57) 0.852 
15 11A 512 498 (2.4) 14 (1.5) 0.71 (0.41–1.23) 0.221 
16§ 23B 499 462 (2.2) 37 (4.0) 1.73 (1.21–2.48) 0.003 
17 15B/C 453 416 (2.0) 37 (4.0) 1.31 (0.91–1.89) 0.146 
18 16F 418 408 (2.0) 10 (1.1) 0.77 (0.41–1.45) 0.415 
19 35F 371 349 (1.7) 22 (2.4) 1.47 (0.93–2.32) 0.096 
20§ 35B 334 308 (1.5) 26 (2.8) 2.12 (1.38–3.25) <0.001 
21 31 282 273 (1.3) 9 (1.0) 1.14 (0.58–2.25) 0.703 
22 20 240 235 (1.1) 5 (0.5) 0.46 (0.19–1.12) 0.086 
23 38 239 229 (1.1) 10 (1.1) 0.79 (0.41–1.54) 0.49 
24 17F 235 221 (1.1) 14 (1.5) 1.71 (0.98–2.98) 0.058 
25 19F 183 171 (0.8) 12 (1.3) 1.24 (0.68–2.28) 0.483 
26 4 135 132 (0.6) 3 (0.3) 0.4 (0.13–1.28) 0.123 
27 14 94 93 (0.4) 1 (0.1) 0.26 (0.04–1.87) 0.18 
28 6A 93 88 (0.4) 5 (0.5) 1.34 (0.52–3.45) 0.538 
29 6B 90 88 (0.4) 2 (0.2) 0.54 (0.13–0.13) 0.397 
30 9V 81 80 (0.4) 1 (0.1) 0.31 (0.04–2.25) 0.245 
31 23F 60 57 (0.3) 3 (0.3) 1.24 (0.38–4.08) 0.722 
32 18C 55 51 (0.2) 4 (0.4) 1.23 (0.43–3.52) 0.701 
33 21 51 47 (0.2) 4 (0.4) 0.8 (0.28–2.3) 0.683 
*Values were adjusted for age and year of diagnosis. Only serotypes responsible for >50 cases of invasive pneumococcal disease were included. aOR, 
adjusted odds ratio. 
†Because of multiple comparisons, a p value of <0.01 was considered significant. 
‡Serotype of decreased odds (decreased aOR with significant p value). 
§Serotype of increased odds (increased aOR and significant p value). 
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caused most meningitis cases (10), consistent with find-
ings in Germany, Belgium, and Brazil (33–35). During 
the PCV7 period, serotypes 7F and 19A (12), among oth-
ers, emerged as the most common replacing serotypes 
causing meningitis in Europe and the United States, main-
ly through clonal expansion (36,37). In several countries, 
including France and the United States but not the United 
Kingdom, isolates of the emerging serotype 19A exhibit-
ed high rates of resistance to multiple antimicrobial drugs 
(38,39). Meningitis caused by serotype 7F has been asso-
ciated with more severe disease (increased complications, 
higher CFR) in children than meningitis caused by other 
serotypes (40).
The replacement of PCV7 with PCV13, which covers 
serotypes 7F and 19A, led to a rapid reduction in IPD, in-
cluding meningitis, caused by these serotypes across all age 
groups. Marked reductions in IPD caused by these 2 sero-
types were observed especially among children <2 years 
of age, the age group in which incidence of pneumococcal 
meningitis is highest (12). By 2015–16, serotypes 8 and 
12F were the main replacing serotypes causing meningitis 
across all age groups.
The predominance of serotype 8 appears to be unique 
to the England and Wales population (41). In Germany, se-
rotypes 14 and 6B pre-PCV7 and serotype 7F post-PCV7 
were the most common; whereas in England and Wales, 
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Figure 4. Distribution of pneumococcal meningitis cases in children <5 years of age, by month of age and Streptococcus pneumoniae 
serotype group, England and Wales, July 1, 2000–June 30, 2016. PCV7 refers to serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, and 
additional PCV13 refers to serotypes 1, 3, 5, 6A, 7F, and 19A. PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent 
pneumococcal conjugate vaccine.
Figure 5. Pneumococcal 
meningitis cases, by 
Streptococcus pneumoniae 
serotype and severity, England 
and Wales, July 1, 2015–June 
30, 2016. We included the non-
PCV13 serotypes that involved 
>10 cases. O, other serotypes; 
PCV7, 7-valent pneumococcal 
conjugate vaccine; PCV13, 
13-valent pneumococcal 
conjugate vaccine.
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serotypes 12F, 8, and 10A caused nearly half of all pneu-
mococcal meningitis cases in patients <5 years of age after 
PCV13 introduction (25). Of the most frequent serotypes 
isolated after PCV13 introduction in France (15B/C, 22F, 
23B, 24F), only 24F had a high disease potential; 5 years 
after PCV13 introduction, no serotype predominated, and 
no significant increase in non–PCV13-type meningitis oc-
curred (42). A common feature shared among countries 
with established PCV13 programs is the high proportion 
of cases (70%–80%) caused by non-PCV13 serotypes after 
PCV13 introduction (20,43).
In our cohort, the differences in disease trends among 
meningitis and nonmeningitis presentations after PCV7 
and PCV13 implementation are probably a result of the 
different propensities of specific serotypes to cause men-
ingitis, pneumonia, severe disease, and fatal outcomes. 
For example, before PCV7 introduction, some PCV7 (6B, 
18C, 19F, 23F), additional PCV13 (3, 6A), and non-PCV13 
(12F) serotypes were more likely to be associated with 
meningitis in the United Kingdom, while serotype 1 (addi-
tional PCV13) was less likely (10). Many of the serotypes 
that increased in incidence after PCV13 implementation 
did not exhibit a higher propensity for causing meningitis. 
Our findings (and those of others) highlight the importance 
of monitoring infectious diseases by their major clinical 
presentations. In the United States, after PCV7 introduc-
tion, the rates of meningitis and invasive pneumonia caused 
by non-PCV7 types increased for all age groups, whereas 
primary bacteremia rates did not change (32). In contrast, 
a study in Spain showed a shift in pneumococcal menin-
gitis cases to persons in older age groups (18). In Canada, 
a higher proportion of IPD cases presented as meningitis 
after the introduction of PCV7 and PCV13 (44), and in Is-
rael, disease caused by non-PCV13 serotypes increased by 
256% for pneumococcal meningitis among children, 302% 
for pneumococcal bacteremic pneumonia, and 116% for 
other IPD presentations (15).
The CFR of our cohort (17.5%, 10.7% in children <5 
years of age) was similar to that reported for the pre-PCV7 
period (14.5%) but higher than that reported for children in 
Spain (5%) and the United States (8.3%–11.2%) (2,18,31). 
We have reported that nearly half of all children with IPD 
who died had meningitis (4) and that meningitis was an 
independent risk factor for death in children with IPD (45). 
Similar to our cohort, studies conducted in other countries 
have also indicated little change in CFR for pneumococ-
cal meningitis after PCV introduction, despite significant 
reductions in disease incidence (18,31,46). Clinical follow-
up of cases suggests that although the risk for pneumococ-
cal meningitis was lowered after PCV introduction, once 
meningitis develops, the outcomes in terms of death or 
long-term sequelae are similar, irrespective of infecting se-
rotype (20). Our finding of lower odds of meningitis but 
higher risk for death with serotype 8 meningitis is novel 
(41) and needs to be verified for other populations.
The strengths of our study included established, long-
term national surveillance along with a national refer-
ence laboratory for IPD covering a large population of 
55 million persons across England and Wales. A study 
limitation was that bacterial meningitis cases caused by 
unknown species types, a substantial proportion of which 
were probably S. pneumoniae, would not have been cap-
tured in the surveillance, thus leading to an underestima-
tion of the burden of pneumococcal meningitis. In ad-
dition, lumbar punctures are less likely to be performed 
on adults than children, and therefore, some IPD cases 
in adults were probably not reported as meningitis. An-
other limitation was that enhanced surveillance with ques-
tionnaires for vaccine-eligible children only began when 
PCV7 was introduced. This change could potentially 
have led to improved ascertainment of meningitis cases in 
the vaccine-eligible cohort after PCV7 introduction and, 
therefore, caused the effects of PCV7 to be underestimat-
ed. On the other hand, cases in and disease trends among 
older children and adults should not have been affected 
because enhanced surveillance was restricted to children 
<5 years of age. Overall, however, these differences were 
unlikely to affect the trends over time, effect of vaccina-
tion, or serotype distribution among meningitis and non-
meningitis cases. Finally, some pneumococcal serotypes 
exhibit cyclical trends, which could potentially explain 
some of the observed changes in serotype distribution; 
we did not evaluate changes in individual serotypes over 
time because of the relatively small numbers of meningi-
tis cases caused by individual serotypes.
Comparisons of our findings with those found in stud-
ies of other populations should be made cautiously because 
of differences in the distribution of serotypes causing inva-
sive disease in persons in different age groups, propensities 
of individual serotypes causing meningitis, replacement se-
rotypes causing disease after PCV7 and PCV13 introduc-
tion, secular trends in non-PCV13 serotypes, vaccination 
schedules and coverage, antimicrobial use, emergence of 
resistant serotypes, clinical practices for investigating and 
treating patients with suspected meningitis, surveillance 
methods, case definitions, and completeness of case ascer-
tainment. Of note, in the United Kingdom, antimicrobial 
resistance among invasive pneumococcal isolates remains 
low (47,48).
In conclusion, the childhood pneumococcal vaccina-
tion program has reduced the incidence of IPD, including 
pneumococcal meningitis, across all age groups through a 
combination of direct and herd protection. We estimated 
that >700 cases of pneumococcal meningitis were prevent-
ed during the first decade of the program, although CFRs 
across different age groups remain relatively unchanged. 
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By 2015–16, most cases of pneumococcal meningitis were 
caused by non-PCV13 serotypes. Further studies are need-
ed to assess the risk factors, clinical course, and outcomes 
of pneumococcal meningitis associated with the replac-
ing serotypes. Higher-valent vaccines are needed to target 
the emerging serotypes in the short term until serotype- 
independent vaccines become available.
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